Generic Tirzepatide: Is There a Generic Zepbound or Mounjaro in 2026?
No. There is no generic tirzepatide, generic Zepbound, or generic Mounjaro in the United States. Tirzepatide is the generic name of both brands, but Eli Lilly's compound patent runs to May 2036 and its formulation patents to 2039, according to the FDA Orange Book. What you can buy today is brand Zepbound from $299/month through LillyDirect, or compounded tirzepatide from $119/month through tracked telehealth providers.
Quick Answer: Is There a Generic Tirzepatide?
There is no generic tirzepatide in 2026. Tirzepatide is the generic name for Zepbound and Mounjaro, but Lilly's core patent (US 9,474,780) is listed by the FDA as expiring May 13, 2036, so no generic version can be approved before then unless a challenger wins in court. The realistic price paths right now are brand Zepbound at $1,060/month list, LillyDirect self-pay vials and KwikPens at $299–$449/month by dose, about $25/month with a covering commercial plan and the savings card, $50/month through the Medicare GLP-1 Bridge Program, or compounded tirzepatide from $119/month (Embody and SnagRx). Across the 42 providers in our GLP-1 Price Index, the median compounded tirzepatide price is $229/month (snapshot September 21, 2026).
Generic Tirzepatide at a Glance
Four numbers explain the whole generic-tirzepatide question: the year the compound patent expires, what the brand costs today, what Lilly charges when you pay cash directly, and the compounded floor.
Patent dates are the FDA Orange Book listings for Zepbound (NDA 217806) and Mounjaro (NDA 215866), read September 23, 2026. Brand prices are Lilly's published list and LillyDirect prices as tracked on our Zepbound cost page. Compounded prices are each tracked provider's advertised monthly price as of September 21, 2026.
What Is the Generic Name for Zepbound and Mounjaro?
The generic name for both Zepbound and Mounjaro is tirzepatide. Zepbound is Eli Lilly's brand of tirzepatide approved for chronic weight management on November 8, 2023; Mounjaro is the same molecule approved for type 2 diabetes on May 13, 2022. Both come in the same 2.5 mg to 15 mg once-weekly doses, and both are covered by the same patents.
“Generic name” and “generic drug” are not the same thing, and the confusion drives most searches for generic Zepbound. Every medicine has a non-proprietary name (tirzepatide, semaglutide, ibuprofen). A generic drug is a separate product, approved by the FDA as equivalent to the brand and sold by another manufacturer once the brand's patents and exclusivities end. Tirzepatide has a generic name but no generic drug. Anyone selling “generic tirzepatide” today is selling either compounded tirzepatide (legal under specific rules, not FDA-approved as a product) or an unapproved import.
Why There Is No Generic Zepbound or Mounjaro: The Patents, With Dates
The FDA Orange Book lists ten Lilly patents against tirzepatide. The one that matters most is US 9,474,780, which covers the molecule itself and expires May 13, 2036; the rest cover the formulation and specific uses and run to 2039 and, for Mounjaro, 2041. A generic manufacturer must either wait for these to expire or prove them invalid or not infringed in court.
Source: FDA Orange Book patent listings for Zepbound (NDA 217806) and Mounjaro (NDA 215866), read September 23, 2026. The Orange Book itself warns that listings do not define the full range of claims a patent holder may assert.
| US patent | Expires | What it covers | Listed for |
|---|---|---|---|
| 9,474,780 | May 13, 2036 | The tirzepatide molecule itself (drug substance) and the finished product | Zepbound + Mounjaro |
| 11,357,820 | Jun 14, 2039 | Drug product (formulation) | Zepbound + Mounjaro |
| 11,918,623 | Jun 14, 2039 | Method of use | Zepbound |
| 12,343,382 | Jul 22, 2039 | Method of use | Zepbound + Mounjaro |
| 12,453,755 | Jun 14, 2039 | Method of use | Mounjaro |
| 12,453,756 | Jun 14, 2039 | Drug product (formulation) | Zepbound + Mounjaro |
| 12,453,758 | Jul 22, 2039 | Method of use | Zepbound |
| 12,616,740 | Jul 22, 2039 | Method of use | Zepbound + Mounjaro |
| 12,629,404 | Jun 14, 2039 | Drug product + method of use | Zepbound + Mounjaro |
| 12,295,987 | Dec 30, 2041 | Method of use | Mounjaro |
FDA exclusivity is separate from patents
On top of patents, the FDA grants fixed exclusivity periods that stop it from accepting or approving a generic application at all. These are short, and for tirzepatide they end years before the patents do:
| Product | Exclusivity | Ends |
|---|---|---|
| Zepbound | NP — New product exclusivity (3 years from the Nov 8, 2023 approval) | Nov 8, 2026 |
| Mounjaro | NCE — New chemical entity exclusivity (5 years from the May 13, 2022 approval) — no generic tirzepatide can be approved before it ends | May 13, 2027 |
| Mounjaro | NPP — New patient population exclusivity (3 years) | Dec 19, 2028 |
Exclusivity codes and durations per the FDA's Frequently Asked Questions on Patents and Exclusivity (NCE = 5 years, new clinical investigation / new product = 3 years).
When Will Tirzepatide Go Generic?
Tirzepatide is not expected to go generic in the United States before May 2036. The dates below are the milestones that actually gate a generic, in order. Only the 2036 and 2039 dates change what a patient can buy.
Zepbound's 3-year new-product exclusivity ends
Zepbound's 3-year new-product exclusivity ends November 8, 2026, but this changes nothing for patients: Lilly's tirzepatide patents still block any generic Zepbound until at least May 13, 2036.
Mounjaro's 5-year new-chemical-entity exclusivity ends
Until May 13, 2027 the FDA cannot approve any generic tirzepatide regardless of patents, because Mounjaro's 5-year new-chemical-entity exclusivity is still running. After that date, approval of a generic waits only on Lilly's patents, which run to May 2036 unless an applicant successfully challenges them.
The tirzepatide compound patent (US 9,474,780) expires
May 13, 2036 is the earliest realistic date a generic tirzepatide could reach US pharmacies, when Lilly's compound patent (US 9,474,780) expires. A generic would still need FDA approval and a formulation that does not infringe the 2039 patents.
Formulation and method-of-use patents expire
Zepbound's formulation patents run to June 14 and July 22, 2039; Mounjaro's last listed use patent runs to December 30, 2041. After these, nothing in the Orange Book stands in the way of a generic.
Two things can move these dates. A generic maker can file a “Paragraph IV” challenge arguing a patent is invalid or not infringed, which starts litigation that Lilly has every incentive to fight. And Lilly can add patents to the Orange Book as new ones issue: four of the ten listed above were added between July 2025 and June 2026. We re-read the listings whenever this page is updated.
Generic, Biosimilar, or Compounded: Which One Applies to Tirzepatide?
A future copy of tirzepatide would be a generic, not a biosimilar. Tirzepatide is a synthetic peptide (molecular weight 4,813.53 daltons per the Mounjaro prescribing information) approved under New Drug Applications, which the Orange Book lists as application type “N”. Copies of NDA drugs go through the abbreviated new drug application (ANDA) pathway, the same route as generic ibuprofen; the biosimilar pathway is reserved for biologics licensed under a BLA, such as insulin or monoclonal antibodies. That matters for price: ANDA generics typically launch at steep discounts once several makers enter, while biosimilars have historically discounted less.
Compounded tirzepatide is neither. It is tirzepatide prepared by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility for an individual prescription. It is not FDA-reviewed as a finished product, it is not “equivalent” in the regulatory sense, and the FDA has warned that unapproved GLP-1 products can carry dosing and quality risks (FDA: concerns with unapproved GLP-1 drugs used for weight loss). It is, however, the only sub-$300 tirzepatide on the market, which is why it is what most “generic tirzepatide” searches end up buying.
Is Compounded Tirzepatide Still Legal Now That the Shortage Is Over?
Yes, under the standard patient-specific rules, but not as a mass-produced copy. The FDA declared the tirzepatide shortage resolved on December 19, 2024 (declaratory order) and gave compounders a wind-down: state-licensed 503A pharmacies until February 18, 2025 and 503B outsourcing facilities until March 19, 2025 (FDA policy statement). Since then a pharmacy can no longer point to the shortage as its legal basis; a prescriber has to write a patient-specific prescription and a licensed pharmacy has to prepare it under the normal compounding rules, which is how the tracked providers below still offer it.
Practically, that means the provider you choose matters more than it did during the shortage. Every provider in our ladder is checked for a named, US-licensed pharmacy in our scoring methodology, and our scam checker flags the ones that hide it. 2 tracked providers in the ladder (Direct Meds GLP-1, Sprout Health) have received an FDA warning letter; the badge links to the letter so you can read it before you decide.
What “Generic Tirzepatide Price” Searches Actually Find: 13 Tracked Compounded Providers, Cheapest First
Advertised monthly price for compounded tirzepatide on each provider's own site, verified for the September 21, 2026 Price Index snapshot. Only providers we track end-to-end are listed. Brand Zepbound lists at $1,060/month and Mounjaro at $1,023/month (Lilly list prices as tracked on our Mounjaro cost page) for comparison; LillyDirect self-pay Zepbound is $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg) per month.
| # | Provider | Tirzepatide / mo | vs Zepbound list | States | |
|---|---|---|---|---|---|
| 1 | Embody#1 pick | $119 | −89% | 48 | Visit Embody |
| 2 | SnagRx | $119 | −89% | 48 | Visit SnagRx |
| 3 | Trimi | $125 | −88% | 47 | Visit Trimi |
| 4 | TMates | $167 | −84% | 45 | Visit TMates |
| 5 | Bodybuilding.com Health+ | $174.67 | −84% | 47 | Visit BB Health+ |
| 6 | bmiMD | $179 | −83% | 48 | Visit bmiMD |
| 7 | DudeMeds | $233 | −78% | 46 | Visit DudeMeds |
| 8 | ShedRx | $239 | −77% | 50 | Visit ShedRx |
| 9 | TrimRx | $259 | −76% | 45 | Visit TrimRx |
| 10 | Enhance MD | $280 | −74% | 50 | Visit Enhance MD |
| 11 | Direct Meds GLP-1FDA letter 2025 | $297 | −72% | 45 | Visit Direct Meds |
| 12 | Sprout HealthFDA letter 2025 | $299 | −72% | 50 | Visit Sprout Health |
| 13 | Willow | $399 | −62% | 50 | Visit Willow |
All 13 tracked tirzepatide providers are shown, cheapest first. Plan terms differ: some headline prices require an annual or multi-month plan, which the tirzepatide cost guide and cheapest tirzepatide ladder spell out row by row. No provider pays for placement.
GLP-1 Price Index: Tirzepatide Market Snapshot (September 21, 2026)
The Index re-verifies every tracked provider's advertised price weekly on the provider's own site. Compounded tirzepatide at $119/month is 9× cheaper than Zepbound's list price and about 60% below LillyDirect's cheapest self-pay dose. Full history on the GLP-1 Price Index.
Does Waiting for a Generic Cost You Anything?
Yes: waiting for a generic tirzepatide means paying brand prices until at least 2036, while compounded tirzepatide already delivers the same molecule from $119/month. The evidence for that molecule is unusually strong: in the SURMOUNT-1 trial (NEJM 2022), adults without diabetes lost an average of 20.9% of body weight on the 15 mg weekly dose over 72 weeks, against 3.1% on placebo. Brand Zepbound is the FDA-reviewed way to get that result; LillyDirect self-pay from $299/month is the cheapest brand path without insurance, and compounded tirzepatide from $119/month is the cheapest path of all, with the trade-off that the finished product is not FDA-reviewed, so pharmacy quality carries the weight the FDA would otherwise carry.
If you have commercial insurance that covers Zepbound, the Lilly savings card can bring the copay to about $25/month for up to 13 fills a year; if you are on Medicare Part D, the GLP-1 Bridge Program has covered Zepbound at $50/month since July 1, 2026. Both are cheaper than any compounded option and are the first things to check. See Zepbound cost and Medicare GLP-1 coverage for eligibility.
Generic Tirzepatide FAQ
Is there a generic tirzepatide?
+
No. As of September 2026, there is no FDA-approved generic tirzepatide in the United States. Tirzepatide is sold only as Eli Lilly's Zepbound (weight loss) and Mounjaro (type 2 diabetes). The FDA Orange Book lists Lilly's tirzepatide compound patent as expiring May 13, 2036, with formulation and method-of-use patents running to June–July 2039 (Zepbound) and December 30, 2041 (Mounjaro), so a generic is not expected before 2036 at the earliest.
What is the generic name for Zepbound?
+
The generic name for Zepbound is tirzepatide. Zepbound is Eli Lilly's brand name for tirzepatide approved for chronic weight management (FDA-approved November 8, 2023). "Generic name" and "generic drug" are different things: tirzepatide is the non-proprietary name of the molecule, but no generic-drug version of tirzepatide is approved or on sale.
What is the generic name for Mounjaro?
+
The generic name for Mounjaro is tirzepatide, the same molecule sold as Zepbound. Mounjaro is the brand approved for type 2 diabetes (May 13, 2022) and Zepbound is the brand approved for weight loss; both contain identical tirzepatide at the same 2.5 mg to 15 mg weekly doses. There is no generic-drug version of Mounjaro.
Is there a generic for Zepbound?
+
No. There is no generic for Zepbound. Lilly's compound patent on tirzepatide (US 9,474,780) is listed in the FDA Orange Book with a May 13, 2036 expiration, and Zepbound's formulation patents run to June 14 and July 22, 2039. The cheapest ways to get tirzepatide today are LillyDirect self-pay Zepbound from $299/month, the Lilly savings card (about $25/month with covering commercial insurance), Medicare's $50/month Bridge Program, or compounded tirzepatide from $119/month.
When will Mounjaro go generic?
+
Mounjaro is not expected to go generic before May 2036. Its 5-year new-chemical-entity exclusivity ends May 13, 2027, which only removes the FDA's regulatory bar on approving a generic; Lilly's tirzepatide compound patent then blocks approval until May 13, 2036, and Mounjaro's last listed method-of-use patent runs to December 30, 2041. A generic maker would have to win a patent challenge to launch earlier.
What is the generic tirzepatide price?
+
There is no generic tirzepatide price because no generic exists. Searches for a "generic tirzepatide price" almost always find compounded tirzepatide, which tracked telehealth providers sell for $119–$399/month (Embody and SnagRx at $119; median $229 across the 42 providers in the GLP-1 Watchdog Price Index, snapshot September 21, 2026). Brand Zepbound lists at $1,060/month and LillyDirect sells self-pay Zepbound for $299–$449/month by dose.
Is compounded tirzepatide the same as generic tirzepatide?
+
No. A generic drug is FDA-approved through an abbreviated new drug application (ANDA) as equivalent to the brand. Compounded tirzepatide is prepared by a state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility for an individual prescription, is not FDA-reviewed as a finished product, and can only be compounded under the standard patient-specific rules now that the FDA declared the tirzepatide shortage resolved on December 19, 2024. It uses the same active molecule, which is why it sells for $119–$399/month instead of $1,060.
When does the tirzepatide patent expire?
+
The core tirzepatide patent (US 9,474,780, covering the molecule) expires May 13, 2036 according to the FDA Orange Book listings for both Zepbound and Mounjaro. Nine further patents covering the formulation and methods of use expire between June 14, 2039 and December 30, 2041. Patent terms can be shortened by successful court challenges or extended by pediatric exclusivity, so the dates are a floor, not a promise.
Sources & References
- FDA Orange Book — Patent and exclusivity listings for Zepbound (NDA 217806)
- FDA Orange Book — Patent and exclusivity listings for Mounjaro (NDA 215866)
- FDA — Frequently Asked Questions on Patents and Exclusivity
- FDA — Declaratory Order: Resolution of Shortages of Tirzepatide Injection (December 19, 2024)
- FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA — FDA's concerns with unapproved GLP-1 drugs used for weight loss
- Jastreboff AM, et al. — Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022
- Eli Lilly — LillyDirect Zepbound self-pay pricing (verified September 19, 2026) and the Mounjaro prescribing information (Description section).